Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications
c-kit, a growth factor receptor with tyrosine kinase activity, plays an important role in the biology of cancer. Its expression has been documented in several malignancies. We performed a retrospective study in 85 patients diagnosed with small cell lung cancer (SCLC) to determine the prevalence and...
Gespeichert in:
Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2006-06, Vol.52 (3), p.343-347 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 347 |
---|---|
container_issue | 3 |
container_start_page | 343 |
container_title | Lung cancer (Amsterdam, Netherlands) |
container_volume | 52 |
creator | Camps, Carlos Sirera, Rafael Bremnes, Roy M. Garde, Javier Safont, María José Blasco, Ana Berrocal, Alfonso Sánchez, José Javier Calabuig, Consuelo Martorell, Miguel |
description | c-kit, a growth factor receptor with tyrosine kinase activity, plays an important role in the biology of cancer. Its expression has been documented in several malignancies. We performed a retrospective study in 85 patients diagnosed with small cell lung cancer (SCLC) to determine the prevalence and role of c-kit as a possible prognostic marker in this lung cancer malignancy. Demographic and clinical data were obtained from patient charts. c-kit, analyzed as immunohistochemical expression in paraffin-embedded tumour tissues, was observed in 60% of patients. All patients were former or present smokers. At diagnosis, 46% of the patients had limited disease (LD) and 54% extended disease (ED). c-kit expression was observed in 59% of LD and 61% of ED patients (
p
=
0.4). Patients received a median of 4 cycles first-line combination chemotherapy (platinum and etoposide). In LD patients, time to progression (TTP) was 11.5 months in c-kit (+) versus 5.9 in c-kit (−) patients (
p
=
0.14), and median survival 15.4 and 12.8 months, respectively (
p
=
0.33). In the ED group, TTP was 5.5 months in c-kit (+) versus 3.8 in c-kit (−) patients (
p
=
0.34), whereas median survival was 6.3 and 7.9 months, respectively (
p
=
0.45). With the limited number of patients in mind, our findings tended towards an association between c-kit expression and survival in the LD group. |
doi_str_mv | 10.1016/j.lungcan.2006.02.003 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67971649</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500206000936</els_id><sourcerecordid>67971649</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-f5f0bc5ffbd498081bac6dda9b89b2d27fab2880452e2bfc0c781b58893838553</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhq2qCLbAT2jlS3tLGDtxbPdSIQQtEhIc6BXLcWzkbT62niwq_75ONxLHXjyy9Mw7rx5CPjIoGbDmYlv2-_HZ2bHkAE0JvASo3pENU5IXqqr4e7LJnC4EAD8hHxC3AEwy0MfkhDVC1lzChjxdjrZ_xYh0CtQVv-JM_Z9d8ohxGmkcKQ6276nz-VkO0nzR-fSVPiT_YnufP9SOHd2l6XmccI6OxmHXR2fnHIBn5CjYHv35Ok_Jz5vrx6sfxd3999ury7vC1ULPRRABWidCaLtaK1Csta7pOqtbpVvecRlsy5WCWnDP2-DAycwIpXSlKiVEdUq-HHJzj997j7MZIi6l7einPZpGasmaWmdQHECXJsTkg9mlONj0ahiYRazZmlWsWcQa4CaLzXuf1gP7dvDd29ZqMgOfV8Cis31I2VPEN05K1ch_Qd8OnM86XqJPBl1cNHYxeTebbor_qfIXgFKaeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67971649</pqid></control><display><type>article</type><title>Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Camps, Carlos ; Sirera, Rafael ; Bremnes, Roy M. ; Garde, Javier ; Safont, María José ; Blasco, Ana ; Berrocal, Alfonso ; Sánchez, José Javier ; Calabuig, Consuelo ; Martorell, Miguel</creator><creatorcontrib>Camps, Carlos ; Sirera, Rafael ; Bremnes, Roy M. ; Garde, Javier ; Safont, María José ; Blasco, Ana ; Berrocal, Alfonso ; Sánchez, José Javier ; Calabuig, Consuelo ; Martorell, Miguel</creatorcontrib><description>c-kit, a growth factor receptor with tyrosine kinase activity, plays an important role in the biology of cancer. Its expression has been documented in several malignancies. We performed a retrospective study in 85 patients diagnosed with small cell lung cancer (SCLC) to determine the prevalence and role of c-kit as a possible prognostic marker in this lung cancer malignancy. Demographic and clinical data were obtained from patient charts. c-kit, analyzed as immunohistochemical expression in paraffin-embedded tumour tissues, was observed in 60% of patients. All patients were former or present smokers. At diagnosis, 46% of the patients had limited disease (LD) and 54% extended disease (ED). c-kit expression was observed in 59% of LD and 61% of ED patients (
p
=
0.4). Patients received a median of 4 cycles first-line combination chemotherapy (platinum and etoposide). In LD patients, time to progression (TTP) was 11.5 months in c-kit (+) versus 5.9 in c-kit (−) patients (
p
=
0.14), and median survival 15.4 and 12.8 months, respectively (
p
=
0.33). In the ED group, TTP was 5.5 months in c-kit (+) versus 3.8 in c-kit (−) patients (
p
=
0.34), whereas median survival was 6.3 and 7.9 months, respectively (
p
=
0.45). With the limited number of patients in mind, our findings tended towards an association between c-kit expression and survival in the LD group.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2006.02.003</identifier><identifier>PMID: 16574270</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Biological and medical sciences ; Biomarkers, Tumor - biosynthesis ; c-kit ; Carcinoma, Small Cell - drug therapy ; Carcinoma, Small Cell - metabolism ; Carcinoma, Small Cell - mortality ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Lung Neoplasms - mortality ; Male ; Medical sciences ; Molecular markers ; Pneumology ; Predictive Value of Tests ; Prevalence ; Prognosis ; Prognostic factors ; Proto-Oncogene Proteins c-kit - biosynthesis ; Retrospective Studies ; Small cell lung cancer (SCLC) ; Survival Rate ; Tumors of the respiratory system and mediastinum</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2006-06, Vol.52 (3), p.343-347</ispartof><rights>2006 Elsevier Ireland Ltd</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-f5f0bc5ffbd498081bac6dda9b89b2d27fab2880452e2bfc0c781b58893838553</citedby><cites>FETCH-LOGICAL-c459t-f5f0bc5ffbd498081bac6dda9b89b2d27fab2880452e2bfc0c781b58893838553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0169500206000936$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17786703$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16574270$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Camps, Carlos</creatorcontrib><creatorcontrib>Sirera, Rafael</creatorcontrib><creatorcontrib>Bremnes, Roy M.</creatorcontrib><creatorcontrib>Garde, Javier</creatorcontrib><creatorcontrib>Safont, María José</creatorcontrib><creatorcontrib>Blasco, Ana</creatorcontrib><creatorcontrib>Berrocal, Alfonso</creatorcontrib><creatorcontrib>Sánchez, José Javier</creatorcontrib><creatorcontrib>Calabuig, Consuelo</creatorcontrib><creatorcontrib>Martorell, Miguel</creatorcontrib><title>Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>c-kit, a growth factor receptor with tyrosine kinase activity, plays an important role in the biology of cancer. Its expression has been documented in several malignancies. We performed a retrospective study in 85 patients diagnosed with small cell lung cancer (SCLC) to determine the prevalence and role of c-kit as a possible prognostic marker in this lung cancer malignancy. Demographic and clinical data were obtained from patient charts. c-kit, analyzed as immunohistochemical expression in paraffin-embedded tumour tissues, was observed in 60% of patients. All patients were former or present smokers. At diagnosis, 46% of the patients had limited disease (LD) and 54% extended disease (ED). c-kit expression was observed in 59% of LD and 61% of ED patients (
p
=
0.4). Patients received a median of 4 cycles first-line combination chemotherapy (platinum and etoposide). In LD patients, time to progression (TTP) was 11.5 months in c-kit (+) versus 5.9 in c-kit (−) patients (
p
=
0.14), and median survival 15.4 and 12.8 months, respectively (
p
=
0.33). In the ED group, TTP was 5.5 months in c-kit (+) versus 3.8 in c-kit (−) patients (
p
=
0.34), whereas median survival was 6.3 and 7.9 months, respectively (
p
=
0.45). With the limited number of patients in mind, our findings tended towards an association between c-kit expression and survival in the LD group.</description><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>c-kit</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Carcinoma, Small Cell - metabolism</subject><subject>Carcinoma, Small Cell - mortality</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular markers</subject><subject>Pneumology</subject><subject>Predictive Value of Tests</subject><subject>Prevalence</subject><subject>Prognosis</subject><subject>Prognostic factors</subject><subject>Proto-Oncogene Proteins c-kit - biosynthesis</subject><subject>Retrospective Studies</subject><subject>Small cell lung cancer (SCLC)</subject><subject>Survival Rate</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhq2qCLbAT2jlS3tLGDtxbPdSIQQtEhIc6BXLcWzkbT62niwq_75ONxLHXjyy9Mw7rx5CPjIoGbDmYlv2-_HZ2bHkAE0JvASo3pENU5IXqqr4e7LJnC4EAD8hHxC3AEwy0MfkhDVC1lzChjxdjrZ_xYh0CtQVv-JM_Z9d8ohxGmkcKQ6276nz-VkO0nzR-fSVPiT_YnufP9SOHd2l6XmccI6OxmHXR2fnHIBn5CjYHv35Ok_Jz5vrx6sfxd3999ury7vC1ULPRRABWidCaLtaK1Csta7pOqtbpVvecRlsy5WCWnDP2-DAycwIpXSlKiVEdUq-HHJzj997j7MZIi6l7einPZpGasmaWmdQHECXJsTkg9mlONj0ahiYRazZmlWsWcQa4CaLzXuf1gP7dvDd29ZqMgOfV8Cis31I2VPEN05K1ch_Qd8OnM86XqJPBl1cNHYxeTebbor_qfIXgFKaeg</recordid><startdate>20060601</startdate><enddate>20060601</enddate><creator>Camps, Carlos</creator><creator>Sirera, Rafael</creator><creator>Bremnes, Roy M.</creator><creator>Garde, Javier</creator><creator>Safont, María José</creator><creator>Blasco, Ana</creator><creator>Berrocal, Alfonso</creator><creator>Sánchez, José Javier</creator><creator>Calabuig, Consuelo</creator><creator>Martorell, Miguel</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060601</creationdate><title>Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications</title><author>Camps, Carlos ; Sirera, Rafael ; Bremnes, Roy M. ; Garde, Javier ; Safont, María José ; Blasco, Ana ; Berrocal, Alfonso ; Sánchez, José Javier ; Calabuig, Consuelo ; Martorell, Miguel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-f5f0bc5ffbd498081bac6dda9b89b2d27fab2880452e2bfc0c781b58893838553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>c-kit</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Carcinoma, Small Cell - metabolism</topic><topic>Carcinoma, Small Cell - mortality</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular markers</topic><topic>Pneumology</topic><topic>Predictive Value of Tests</topic><topic>Prevalence</topic><topic>Prognosis</topic><topic>Prognostic factors</topic><topic>Proto-Oncogene Proteins c-kit - biosynthesis</topic><topic>Retrospective Studies</topic><topic>Small cell lung cancer (SCLC)</topic><topic>Survival Rate</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Camps, Carlos</creatorcontrib><creatorcontrib>Sirera, Rafael</creatorcontrib><creatorcontrib>Bremnes, Roy M.</creatorcontrib><creatorcontrib>Garde, Javier</creatorcontrib><creatorcontrib>Safont, María José</creatorcontrib><creatorcontrib>Blasco, Ana</creatorcontrib><creatorcontrib>Berrocal, Alfonso</creatorcontrib><creatorcontrib>Sánchez, José Javier</creatorcontrib><creatorcontrib>Calabuig, Consuelo</creatorcontrib><creatorcontrib>Martorell, Miguel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Camps, Carlos</au><au>Sirera, Rafael</au><au>Bremnes, Roy M.</au><au>Garde, Javier</au><au>Safont, María José</au><au>Blasco, Ana</au><au>Berrocal, Alfonso</au><au>Sánchez, José Javier</au><au>Calabuig, Consuelo</au><au>Martorell, Miguel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2006-06-01</date><risdate>2006</risdate><volume>52</volume><issue>3</issue><spage>343</spage><epage>347</epage><pages>343-347</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>c-kit, a growth factor receptor with tyrosine kinase activity, plays an important role in the biology of cancer. Its expression has been documented in several malignancies. We performed a retrospective study in 85 patients diagnosed with small cell lung cancer (SCLC) to determine the prevalence and role of c-kit as a possible prognostic marker in this lung cancer malignancy. Demographic and clinical data were obtained from patient charts. c-kit, analyzed as immunohistochemical expression in paraffin-embedded tumour tissues, was observed in 60% of patients. All patients were former or present smokers. At diagnosis, 46% of the patients had limited disease (LD) and 54% extended disease (ED). c-kit expression was observed in 59% of LD and 61% of ED patients (
p
=
0.4). Patients received a median of 4 cycles first-line combination chemotherapy (platinum and etoposide). In LD patients, time to progression (TTP) was 11.5 months in c-kit (+) versus 5.9 in c-kit (−) patients (
p
=
0.14), and median survival 15.4 and 12.8 months, respectively (
p
=
0.33). In the ED group, TTP was 5.5 months in c-kit (+) versus 3.8 in c-kit (−) patients (
p
=
0.34), whereas median survival was 6.3 and 7.9 months, respectively (
p
=
0.45). With the limited number of patients in mind, our findings tended towards an association between c-kit expression and survival in the LD group.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>16574270</pmid><doi>10.1016/j.lungcan.2006.02.003</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0169-5002 |
ispartof | Lung cancer (Amsterdam, Netherlands), 2006-06, Vol.52 (3), p.343-347 |
issn | 0169-5002 1872-8332 |
language | eng |
recordid | cdi_proquest_miscellaneous_67971649 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage Biological and medical sciences Biomarkers, Tumor - biosynthesis c-kit Carcinoma, Small Cell - drug therapy Carcinoma, Small Cell - metabolism Carcinoma, Small Cell - mortality Female Gene Expression Regulation, Neoplastic Humans Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - mortality Male Medical sciences Molecular markers Pneumology Predictive Value of Tests Prevalence Prognosis Prognostic factors Proto-Oncogene Proteins c-kit - biosynthesis Retrospective Studies Small cell lung cancer (SCLC) Survival Rate Tumors of the respiratory system and mediastinum |
title | Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T03%3A07%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20c-kit%20expression%20in%20small%20cell%20lung%20cancer:%20Prevalence%20and%20prognostic%20implications&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Camps,%20Carlos&rft.date=2006-06-01&rft.volume=52&rft.issue=3&rft.spage=343&rft.epage=347&rft.pages=343-347&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/j.lungcan.2006.02.003&rft_dat=%3Cproquest_cross%3E67971649%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67971649&rft_id=info:pmid/16574270&rft_els_id=S0169500206000936&rfr_iscdi=true |